Fulcrum Therapeutics (FULC) to Release Earnings on Monday

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) is scheduled to announce its earnings results before the market opens on Monday, May 13th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last released its earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.04. Fulcrum Therapeutics had a negative return on equity of 36.65% and a negative net margin of 3,470.05%. The business had revenue of $0.87 million during the quarter, compared to the consensus estimate of $0.65 million. On average, analysts expect Fulcrum Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Fulcrum Therapeutics Price Performance

Shares of NASDAQ FULC traded down $0.21 during trading on Tuesday, reaching $7.54. 313,442 shares of the stock traded hands, compared to its average volume of 613,355. The stock has a market capitalization of $468.61 million, a P/E ratio of -4.77 and a beta of 2.35. Fulcrum Therapeutics has a 52-week low of $2.65 and a 52-week high of $13.70. The company has a 50-day moving average of $9.00 and a 200-day moving average of $7.17.

Insider Activity at Fulcrum Therapeutics

In other Fulcrum Therapeutics news, VP Greg Tourangeau sold 4,884 shares of the stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $11.72, for a total value of $57,240.48. Following the sale, the vice president now directly owns 11,807 shares in the company, valued at approximately $138,378.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.10% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have commented on FULC. Royal Bank of Canada began coverage on shares of Fulcrum Therapeutics in a report on Wednesday, March 13th. They set an "outperform" rating and a $14.00 price objective on the stock. HC Wainwright raised their price objective on shares of Fulcrum Therapeutics from $14.00 to $17.00 and gave the stock a "buy" rating in a report on Wednesday, February 28th. The Goldman Sachs Group lifted their price objective on shares of Fulcrum Therapeutics from $5.00 to $6.00 and gave the company a "neutral" rating in a research note on Thursday, January 25th. Finally, Piper Sandler increased their target price on Fulcrum Therapeutics from $13.00 to $15.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 28th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $13.17.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.